Kyverna Therapeutics, Inc. · NASDAQ:KYTX
Kyverna Therapeutics — Investor Presentation (January 2025)
29 slides from Kyverna Therapeutics's investor presentation, Jan 13, 2025
Slide 1: Pioneering CAR T in Autoimmune Diseases
Cindy Patient warrior Pioneering CAR T in Autoimmune Diseases January 2025 Exhibit 99.2
Slide 2: Forward-looking statements
2 This presentation contains forward - looking statements that are based on management’s beliefs and assumptions and on information currently available to management of Kyverna Therapeutics, Inc. (“Kyverna”, “we”, “our,” or the “Company”). All statements other than statements of historical facts con
Slide 3: Liberating Autoimmune Patients through the Curative Potential of Cell Therapy
3 LIBERATING AUTOIM MUNE PATIENTS through the CURATIVE POTENTIAL OF CELL THERAPY Robert, Patient warrior Cindy, Patient warrior Roger, Patient warrior Bryce, Patient warrior
Slide 4: 2025: Kyverna's Transformative Year with Multiple Near-Term Catalysts
4 2025: Kyverna’s Transformative Year with Multiple Near - Term Catalysts Pivoting to Late - Stage Development and Commercialization FAST FOLLOW Accelerating MG and LN Phase 1 LN data and interim Phase 2 MG dat a expected in 2H 2025 FURTHER Expand into Broader Autoimmune Indications KYV - 102 IND fi
Slide 5: Manufacturing Excellence and Innovation, Unique CAR T Construct
5 Manufacturing Excellence and Innovation Unique CAR T Construct RMAT, Regenerative Medicine Advanced Therapy; ODD, Orphan Drug Designation
Slide 6: Prioritized Portfolio Unlocks Opportunities across Neuroinflammatory and Rheumatologic Diseases
6 Prioritized Portfolio Unlocks Significant Opportunities across Neuroinflammatory and Rheumatologic Diseases Stiff person Syndrome Myasthenia Gravis Lupus Nephritis SPS is the tip of the spear… Future Potential Indications 1) Published literature through GlobalData market analysis reports and inter
Slide 7: Stiff Person Syndrome: Deliver Pivotal Phase 2 Study, Prepare for BLA Filing
7 RMAT designation and potential for 1 st CAR T approved in autoimmune Pivotal Phase 2 is 40% enrolled with registrational intent No currently approved therapies High chronic cost burden Source for market size: Analysis of Komodo Health claims data; Yi J, et al. Neurol. Neuroimmunol. Neuroinflamm. (
Slide 8: Previously presented at ECTRIMS in SPS: Strong Clinical Activity
8 Previously presented at ECTRIMS KYV - 101 in SPS: Demonstrates Strong Clinical Activity and Potential for Deep Responses Kyverna Experience at Therapeutic Dose in Initial 3 Patients *Data on walking speed available for 2 of 3 patients . † Data shown for immunosuppressant and immunomodulatory agent
Slide 9: Myasthenia Gravis: Fast Follow Indication, Significant Unmet Need
9 Myasthenia Gravis: Fast Follow Indication, Significant Unmet Need RMAT designation with fast follow intent Phase 2 actively enrolling and dosing patients Synergistic commercial infrastructure to SPS Available therapies remain suboptimal with significant cost burden Source for market size: Analysis
Slide 10: Previously presented at ECTRIMS in MG: Rapid and Sustained Disease Control
10 Previously presented at ECTRIMS KYV - 101 in MG: Has Demonstrated Rapid and Sustained Disease Control Kyverna Experience at Therapeutic Dose in Initial 3 Patients 0 2 4 6 180 150 120 90 60 30 BL *Data shown for immunosuppressant and immunomodulatory agents only; does not include physiologic repla
Slide 11: Lupus Nephritis: High Burden of Disease Progression
11 Lupus Nephritis: High Burden of Disease Progression Source for market size: GlobalData SLE Forecast 2021; Hocaoglu M, et al. Arthritis Rheumatol. (2023) (LUMEN Study); Helmick C G, et al. Arthritis & Rheumatism. (2008); Gasparotto M, et al. Rheumatology. (2020) Source for ESRD progression: Lateef
Slide 12: Previously presented at ACR Convergence in LN
12 Previously presented at ACR Convergence KYV - 101 in LN: Redefining Clinical Success and Delivering First CAR T Rheumatology Indication Kyverna Experience at Therapeutic Dose in Initial 4 Patients Median anti - dsDNA titer, IU/mL (SE) *Data shown for immunosuppressant and immunomodulatory agents
Slide 13: Driving Durable Remissions at Therapeutic Dose
13 KYV - 101: Driving Durable Remissions at Therapeutic Dose Note: named patient data. KYV - 101 therapeutic dose is 1 × 10 8 CAR T cells/ μ L. References: 1. Haghikia A, et al. Lancet Neurol. 2023;22:1104 - 5. 2. Unpublished data. 3. Faissner S, et al. PNAS. 2024;21:e24032 27121. 4. Kyverna Symposi
Slide 14: Denise, MG Warrior
14 Uncontrollable Myasthenia Gravis Recurrent Flares Frequent Hospitalizations Intubations Tracheostomy Feeding Tube Denise, MG Warrior
Slide 15: Dosed with
15 Dosed with KYV - 101
Slide 16: 16
16
Slide 17: Reimagining the Next Generation of CAR T Patient Delivery with KYV-102
17 Reimagining the Next Generation of CAR T Patient Delivery with KYV - 102 No Apheresis, Reduces Costs, Improves Patient Access KYV - 102 KYV - 101 Begins with apheresis Begins with whole blood – no need for apheresis 7 - 10 day culture time <3 - day culture time TARGETED BENEFITS • Improve patient
Slide 18: Focused 2025 Pipeline Priorities
18 Regulatory Milestone Phase 3* Phase 2 Phase 1 Preclinical Candidate Indication RMAT, ODD KYV - 101 Stiff person syndrome RMAT, ODD**, FTD KYV - 101 Myasthenia gravis FTD KYV - 101 Lupus nephritis KYV - 102 Whole Blood Next - Gen Process *Phase 3 may not be required if Phase 2 is registrational Fa
Slide 19: Uniquely Designed for Autoimmune Diseases
19 KYV - 101: Uniquely Designed for Autoimmune Diseases KYV - 101 Fully Human Design Anti - CD19 scFv CD8 α TM CD28 Costim CD3 ζ C D8 α Hinge Designed for POTENCY • Differentiated CD19 with highly potent CD28 costimulation • Deep B - cell depletion and immune reset Delivering TRANSFORMATIVE CLINICAL
Slide 20: A Fundamentally Different Approach
20 KYV - 101 is a Fundamentally Different Approach Goals of KYV - 101 DEEP B CELL DEPLETION and IMMUNE RESET ELIMINATION of chronic therapy % SINGLE administration 1 Transformative outcomes with CURATIVE POTENTIAL Disease Modification Aim to slow or stop progression Aim for long - term remission wit
Slide 21: Near-Term Milestones to Drive Value Creation
21 Near - Term Milestones to Drive Value Creation Milestones Program Complete Pivotal Phase 2 Enrollment mid - 2025 Report Topline Pivotal Phase 2 Data 1H 2026 BLA filing in 2026 Stiff Person Syndrome RMAT Designation Confirm Registrational Path with Regulators 1H 2025 Report Interim Phase 2 Data 2H
Slide 22: 2025 Priorities to Rapidly Deliver to Market
22 2025 Priorities to Rapidly Deliver KYV - 101 to Market Transformative year to support late - stage development and commercialization of KYV - 101 On track to deliver the FIRS T autoimmune CAR T approved in neuroinflammatory disease with SPS BLA filing targeted for 2026 FAST - follow indications i
Slide 23: Appendix
Roger Patient warrior Appendix
Slide 24: Anti-CD19 CAR T therapy deeply depletes B cells in blood and tissues
24 Anti - CD19 CAR T therapy deeply depletes B cells in blood and tissues and disrupts B cell follicular architecture, with the aim of triggering an immune reset Tur C, et al. Ann Rheum Dis. 2024 Sep 11;0:1 – 8:ard - 2024 - 226142. Before Treatment CD19+ Significant Reduction in B Cell Architecture
Slide 25: KYSA Trials Position on Rapid Path to Market in Priority Indications
25 KYSA Trials Position KYV - 101 on Rapid Path to Market in Priority Indications Lupus Nephritis Myasthenia Gravis Stiff Person Syndrome KYSA - 1 & KYSA - 3 KYSA - 6 KYSA - 8 Study Name US & EU US & EU US Location Phase 1 Phase 2 Phase 2 Study Phase NCT05938725 & NCT 06342960 NCT06193889 NCT0658849
Slide 26: Leading Patient Experience Across Diverse Indications
26 Kyverna’s Leading Patient Experience with KYV - 101 Across diverse indications treated with KYV - 101 1 50+ Autoimmune Patients 15+ Autoimmune Indications • Stiff person syndrome • Myasthenia gravis • Multiple sclerosis • NMOSD • CIDP • Rheumatoid arthritis • Systemic sclerosis • Lupus nephritis
Slide 27: Initially Focused on Three Indications with High Unmet Need
27 Initially Focused on Three Indications with High Unmet Need; Potential for KYV - 101 to Deliver Differentiated Benefit Significant area of Unmet need Transformative outcomes in established market Lead indication, establishes commercial infrastructure 70,000 – 100,000 80,000 – 100,000 2,000 - 6,00
Slide 28: Proven Leadership Team with Significant CAR T and Autoimmune Experience
28 Cara Bauer Chief Human Resources Officer Proven Leadership Team with Significant CAR T and Autoimmune Experience Dominic Borie, MD, PhD President, Research and Development Karen Walker Chief Technology Officer Ryan Jones, MBA Chief Financial Officer Tom Van Blarcom, PhD Senior Vice President and
Slide 29: Strong Financial Position to Deliver Key Milestones
29 Strong Financial Position to Deliver Key Milestones Cash, cash equivalents and marketable securities (as of Sep 30, 2024) ~43M Shares Outstanding (as of Oct 31, 2024) ~$ 321.6M ~$24.6M Q3 Operating Cash Burn (3 months ended Sep 30, 2024)
Kyverna Therapeutics — Investor Presentation (January 2025) on 6ix